Page contentsPage contents Key facts Decision Key facts Active substance Olpasiran Therapeutic area Cardiovascular diseases Decision number P/0081/2021 PIP number EMEA-002910-PIP01-20 Pharmaceutical form(s) Solution for injection Condition(s) / indication(s) Prevention of cardiovascular events Route(s) of administration Subcutaneous use Contact for public enquiries Amgen Europe B.V. E-mail: medinfointernational@amgen.comTel. +44 (0)1223 420305 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 17/03/2021 Compliance check done No Decision P/0081/2021 : EMA decision of 17 March 2021 on the granting of a product specific waiver for olpasiran (EMEA-002910-PIP01-20)Adopted Reference Number: EMA/97658/2021 English (EN) (200.06 KB - PDF)First published: 09/11/2021 View Share this page